Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hi-LiGHT real-world long-term study of bimekizumab in hidradenitis suppurativa
NL-OMON58141Phase 4Recruiting
- Sponsor
- UCB
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimekizumab in hidradenitis suppurativa (HS), sponsored by UCB. Primary endpoint: IHS4-55 response at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON58141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58141.